In addition to breast cancer, ESR1, ESR2, and PGR also mediate the progression of prostate cancer (13–15), colon cancer (16–18), ovarian cancer (19–21), and lung cancer (22–24). This evidence concerns the gene ESR2 and breast carcinoma.